Interventional therapy for lung cancer

Clinical efficiency of drug-eluting beads bronchial artery embolization for locally advanced non-small cell lung cancer after failure of concurrent chemoradiotherapy

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2000040544

Enrollment

Unknown

Registered

2020-12-01

Start date

2021-07-01

Completion date

Unknown

Last updated

2021-03-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lung cancer

Interventions

treatment group:drug-eluting beads of bronchial artery embolization

control group:chemotherapy

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1) Histopathologically confirmed non-small cell lung cancer; 2) Clinical diagnosis of advanced non-small cell lung cancer;After previous first-line treatment, local tumor volume progressed to > 20%. 3) The expected survival time of the patient is more than 3 months; 4) KPS score >60, ECOG score <=2; 5) Cardiopulmonary function is basically normal; 6) The patient signed the informed consent to the experimental study and promised to be followed up.

Exclusion criteria

Exclusion criteria: 1) Severe leukopenia and thrombocytopenia are difficult to correct; 2) Cachexia or failure of heart, lung, liver, kidney and other organs; 3) It is contraindicated if the bronchial artery and spinal artery are co-trunk or anastomosed; 4) Those allergic to contrast agents.

Design outcomes

Primary

Measure	Time frame
Progress-free time;overall survival;	—

Countries

China

Contacts

Public ContactWang Yongzheng

Department of Interventional Medicine, The Second Hospital,Cheeloo College of Medicine, Shandong University

shuijing_0318@126.com+86 18253132618

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026